Financial Performance - The company's revenue for Q1 2025 was ¥577,383,322.42, representing a decrease of 40.35% compared to ¥967,900,022.68 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥49,271,134.83, a decline of 171.09% from a profit of ¥69,305,423.83 in the previous year[4] - The net cash flow from operating activities decreased by 44.54%, amounting to ¥81,041,633.19 compared to ¥146,130,897.27 in the prior year[4] - Total operating revenue for Q1 2025 was ¥577.38 million, a decrease of 40.4% compared to ¥967.90 million in Q1 2024[17] - Net profit for Q1 2025 was a loss of ¥49.50 million, compared to a profit of ¥69.12 million in Q1 2024, indicating a significant decline[18] - Operating profit for Q1 2025 was a loss of ¥58.45 million, contrasting with a profit of ¥80.36 million in Q1 2024[17] - Cash flow from operating activities for Q1 2025 was ¥81.04 million, down 44.5% from ¥146.13 million in Q1 2024[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,611,332,242.14, a decrease of 2.21% from ¥5,738,112,424.72 at the end of the previous year[5] - The company's current assets totaled RMB 3,037,807,721.74, down from RMB 3,157,931,976.13, indicating a decrease of about 3.8%[12] - Cash and cash equivalents increased to RMB 1,454,983,942.63 from RMB 1,331,795,660.80, representing a growth of approximately 9.2%[12] - Inventory decreased significantly from RMB 757,335,702.72 to RMB 645,468,495.43, a reduction of around 14.7%[12] - Total liabilities decreased from RMB 2,153,155,749.09 to RMB 2,075,873,810.65, a decline of about 3.6%[14] - The company's equity attributable to shareholders decreased from RMB 3,577,629,966.77 to RMB 3,528,358,831.94, a decrease of approximately 1.4%[14] - The company reported a short-term loan of RMB 103,133,365.43, down from RMB 112,965,265.65, reflecting a decrease of about 8.0%[14] - The company's accounts receivable stood at RMB 575,284,268.66, a slight decrease from RMB 611,698,533.96, indicating a reduction of approximately 6.0%[12] - The company's total non-current assets were RMB 2,573,524,520.40, slightly down from RMB 2,580,180,448.59, reflecting a decrease of about 0.3%[13] Research and Development - Research and development expenses totaled ¥99,271,226.53, which is an increase of 2.27% year-over-year, and accounted for 17.19% of total revenue, up by 10.03 percentage points[5] - The company is actively promoting and increasing investment in key R&D projects, including small nucleic acid drugs and peptide drugs, to maintain industry leadership[7] - Research and development expenses for Q1 2025 were ¥97.17 million, an increase of 13.6% from ¥85.50 million in Q1 2024[17] Sales and Marketing - The company plans to optimize sales strategies and maintain core sales channels to address the decline in revenue and profit[7] - Sales expenses for Q1 2025 were ¥130.66 million, down 55.6% from ¥294.03 million in Q1 2024[17] Financial Metrics - The weighted average return on equity was -1.39%, down by 3.31 percentage points from 1.92% in the previous year[4] - The basic and diluted earnings per share were both -¥0.11, a decrease of 173.33% from ¥0.15 in the same period last year[4] - The company incurred a financial expense of ¥3.61 million in Q1 2025, compared to a financial income of ¥0.54 million in Q1 2024[17]

Financial Performance - The company reported a basic earnings per share of -0.1100 yuan for Q1 2025, a decrease of 173.33% compared to 0.1500 yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 5.77 billion yuan, down 40.39% from 9.68 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.49 billion yuan, representing a decline of 171.01% from a profit of 0.69 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -1.39%, a significant drop from 1.92% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 25,836.88 million shares, accounting for 57.42% of the circulating shares, with a decrease of 1,485.70 million shares compared to the previous period [1] - The largest shareholder, Fuyang Jingyue Yongshun Information Consulting Co., Ltd., holds 18,024.01 million shares, representing 40.05% of the total share capital, with no change [2] - Hong Kong Central Clearing Limited and China Merchants Medical Health Industry Stock have exited the top ten shareholders list [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 悦康药业集团股份有限公司（以下简称"公司"或"悦康药业"）控股股东 阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持有公司股份 180,240,120 股，占公司总股本的比例为 40.05%。截至本公告披露日，本次京悦 永顺持有的本公司 26,500,000 股无限售流通股股票将被司法拍卖。 目前拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行法定 程序、股权变更过户等环节，存在一定的不确定性。公司将根据最终结果，依法 履行相应的信息披露义务。 拍卖成交后，买受人后续减持股票需符合《上市公司股东减持股份管理 暂行办法》及《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、 高级管理人员减持股份（2025 年 3 月修订）》等相关规定。同时买受人还需遵守 中国证监会、上海证券交易所等关于上市公司信息披露的相关规定，依法履行信 息披露义务。股票后续能否立即在二级市场进行交易，具体的情况应以监管部门 的认定为准。 京悦永顺持有的部分本公司股份 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-020 悦康药业集团股份有限公司 关于控股股东部分股份被冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、公司股东股份被冻结的具体情况 股东 名称 是否为控 股股东及 其一致行 动人 冻结股份数 量 占其 所持 股份 比例 占公 司总 股本 比例 冻结股 份是否 为限售 股 冻结起始日 冻结到期日 冻结申请人 冻结 原因 京悦 永顺 是 13,130,000 7.28% 2.92% 否 2025 年 1 月 20 日 2028 年 1 月 19 日 宁波惟精昫竔 股权投资合伙 企业（有限合 伙）、宁波焓湜 枫德股权投资 合伙企业（有限 合伙） 财产 保全 是 2,066,002 1.15% 0.46% 否 2025 年 1 月 27 日 2028 年 1 月 26 日 合计 - 15,196,002 8.43% 3.38% - - - - - 司法冻结，具体情况如下： 悦康药业集团股份有限公司（以下简称"公司"）控股股东阜阳京悦永 ...

截至2025年4月14日 11:30，上证科创板综合指数(000680)强势上涨1.13%，成分股悦康药业(688658)上涨19.99%，科兴制药(688136)上涨17.23%，智翔金泰 (688443)上涨11.27%，和元生物(688238)，路德环境(688156)等个股跟涨。科创综指ETF华夏(589000)上涨1.19%， 冲击5连涨。最新价报0.94元。 流动性方面，科创综指ETF华夏盘中换手23.24%，成交1.97亿元，市场交投活跃。 自2025年4月2日，美国政府宣布对中国输美商品征收34%的所谓"对等关税"以来，对于关税税率及医药商品豁免政策反复调整，而中国积极应对美国关税政 策，截至2025年4月11号，中美双边商品贸易关税税率均已调整至125%，中方表示如果美方后续对中国输美商品继续加征关税，中方将不予理会。 平安证券指出，介于中美关税政策调整频繁，预期短期将持续扰动中美医药商品贸易，而以美国以外市场为主要出口方向的出海企业影响较小。此外中国对 美加关税有望推动部分美国产品市占率较高的生物医药产品进口替代进程。 该机构表示建议关注"创新"、"出海"、"设备更新"与"消费复苏"。 科 ...

中国北京市朝阳区北辰东路八号 北辰汇宾大厦 A 座六层 邮编：100101 F6/A，North Star HuiBin Plaza, No.8 BeiChen East Road, ChaoYang District, BeiJing 100101 China 北京天驰君泰律师事务所 关于悦康药业集团股份有限公司 2024 年年度股东会 的 法律意见书 北京 上海 广州 深圳 天津 长春 南京 郑州 成都 福州 Beijing, Shanghai, Guangzhou, Shenzhen, Tianjin, Changchun, Nanjing, Zhengzhou, Chengdu, Fuzhou, 北京天驰君泰律师事务所 关于悦康药业集团股份有限公司 2024 年年度股东会的法律意见书 致：悦康药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》等相关法律、行政法规，以及中国证券监督管理委员会发布 的《上市公司股东会规则》（以下简称"《股东会规则》"）等规范性文件以 及《悦康药业集团股份有限公司章程》（以下简称"《公司章程》"）的规 定，北京天驰君泰律 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-019 悦康药业集团股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 9 日 （二） 股东大会召开的地点：北京市北京经济技术开发区科创七街 11 号悦康创 新药物国际化产业园一楼会议室。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 141 | | --- | --- | | 普通股股东人数 | 141 | | 2、出席会议的股东所持有的表决权数量 | 236,880,862 | | 普通股股东所持有表决权数量 | 236,880,862 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 53.2938 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

Core Viewpoint - The company is celebrating its 40th anniversary in the pharmaceutical industry, marking significant achievements in both generic and innovative drug development, with a clear focus on biopharmaceuticals and internationalization as key strategic directions [2][4][8]. Group 1: Company History and Development - The company was founded in 2001 by Yu Weishi, who aimed to provide affordable and high-quality medicines during a time of rapid growth in the Chinese pharmaceutical market [3]. - Initially focused on generic drug production, the company achieved significant milestones with products like Omeprazole enteric-coated capsules and Ginkgo biloba extract injection, with several products generating annual sales exceeding 1 billion or even 10 billion [3][4]. - By 2012, the company began integrating innovation into its strategy, launching its first Class 1 new drug project and later developing the first domestically produced anti-ED drug [4][5]. Group 2: Research and Development Strategy - The company has established a robust R&D team of over 500 members, collaborating with prestigious institutions to accelerate the translation of research into practical applications [5][6]. - Current R&D strategies focus on innovative drugs targeting cardiovascular diseases, cancer, and infectious diseases, while also developing high-end generic drugs with technical barriers [6][7]. - As of the end of 2024, the company has 42 ongoing research projects, including 21 innovative drugs and 21 generic drugs [4][6]. Group 3: Innovative Drug Pipeline - Several innovative drugs are in the application stage for market approval, including mRNA vaccines and nucleic acid drugs, with significant advancements in clinical trials [7][9]. - The company is actively pursuing breakthroughs in biopharmaceuticals, with a focus on nucleic acid and gene therapy, and aims to have multiple projects entering the application or clinical registration phases annually [7][9]. Group 4: Technological Advancements - The company has invested heavily in new technologies, with R&D expenditures reaching 422 million yuan, accounting for 11.16% of revenue, and has developed eleven major technology platforms [9][10]. - Innovations include breakthroughs in mRNA vaccine technology and AI integration in drug development processes, enhancing efficiency and effectiveness [10][12]. - A strategic partnership with Huawei has been established to advance digital transformation within the pharmaceutical industry [11].

悦康药业集团股份有限公司 2024 年年度股东大会会议资料 悦康药业集团股份有限公司 会议资料 悦康药业集团股份有限公司 2024 年 年度股东大会会议资料 悦康药业集团股份有限公司 2024 年年度股东大会会议资料 目 录 悦康药业集团股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会 规则》以及《悦康药业集团股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，认真做好召开股东大会的各项工作，特制定本须知： 九、本公司不向参加股东大会的股东发放礼品，不负责安排参加股东大会股 东的住宿等事项，以平等对待所有股东。 悦康药业集团股份有限公司 一、为保证股东大会的严肃性和正常秩序，切实维护股东的合法权益，除出 席会议的股东及股东代表、董事、监事、公司高级管理人员、公司聘任律师及中 介机构外，公司有权依法拒绝其他人员入场。 二、请出席会议的股东及股东代表在会议召开前 20 分钟到达会议现场办理 签到手续。大会工作人员将对出席会议者的身 ...

悦康药业集团股份有限公司 2024 年年度股东大会会议资料 悦康药业集团股份有限公司 2024 年年度股东大会 会议资料 2025 年 4 月 | 2024 | 年年度股东大会会议须知 2 | | --- | --- | | 2024 | 年年度股东大会会议议程 4 | | 2024 | 年年度股东大会会议议案 6 | 悦康药业集团股份有限公司 2024 年年度股东大会会议资料 悦康药业集团股份有限公司 2024 年年度股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会 规则》以及《悦康药业集团股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，认真做好召开股东大会的各项工作，特制定本须知： 一、为保证股东大会的严肃性和正常秩序，切实维护股东的合法权益，除出 席会议的股东及股东代表、董事、监事、公司高级管理人员、公司聘任律师及中 介机构外，公司有权依法拒绝其他人员入场。 二、请出席会议的股东及股东代表在会议召开前 20 分钟 ...